Aromatase inhibitors inhibit breast cancer growth by estrogen deprivation and, therefore, ESR1 mutations confer resistance to aromatase inhibition because they allow tumors to proliferate independently of estrogen. This evidence concerns the gene CYP19A1 and breast cancer.